Plain-English translation of NCT05055908 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Researchers are studying patients with lung cancer who are being treated with immune checkpoint inhibitors — a type of medication that helps the body fight cancer — either alone or combined with chemotherapy. By collecting blood samples and tracking side effects, the study aims to identify genetic markers that predict which patients will experience serious adverse reactions, so doctors can better personalize treatment in the future.
Immune checkpoint inhibitors have helped many lung cancer patients, but they can cause unpredictable and sometimes serious side effects. This trial exists to find early warning signs — based on a patient's genetics — so doctors can predict who might struggle with this medication and adjust treatment plans accordingly.
You likely qualify if…
You likely don't qualify if…
You will receive your regular lung cancer treatment (immune therapy alone or with chemotherapy) as planned with your doctor. The study involves donating blood samples at the start of treatment and during follow-up visits so researchers can analyze your genes. You will also work with the research team to report any side effects you experience. The study includes about 12,000 patients total, divided into groups based on the type of treatment they receive.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China